Inhibrx Biosciences: Potential Blockbuster Cancer Drug Sparks Bidding War

Inhibrx Biosciences has caught the attention of prominent pharmaceutical companies, such as Merck & Co and Ono Pharmaceutical, for their experimental cancer treatment, INBRX-106. The San Diego-based biotech is evaluating a joint spin-off that includes INBRX-106 and another promising cancer treatment, which together may be valued over $9 billion.

Interest primarily centers on INBRX-106, currently being trialed alone and in combination with Merck's leading drug, Keytruda. The company believes their drug has the potential to enhance Keytruda's effectiveness, a medication that significantly contributes to Merck's annual global sales. Discussions, however, are still in early stages.

Despite no official comments from the companies involved, market reactions have been significant. Inhibrx's stock experienced a surge after reports circulated, with predictions that their second drug, ozekibart, could eventually achieve $10 billion in annual sales, offering promising results against Ewing sarcoma and colorectal cancer.